Revenue Showdown: Arrowhead Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.

Pharma Giants' Revenue Battle: Amphastar vs. Arrowhead

__timestampAmphastar Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.
Wednesday, January 1, 2014210461000175000
Thursday, January 1, 2015251519000382000
Friday, January 1, 2016255165000158333
Sunday, January 1, 201724017500031407709
Monday, January 1, 201829466600016142321
Tuesday, January 1, 2019322357000168795577
Wednesday, January 1, 202034984600087992066
Friday, January 1, 2021437768000138287000
Saturday, January 1, 2022498987000243231000
Sunday, January 1, 2023644395000240735000
Monday, January 1, 20243551000
Loading chart...

Unveiling the hidden dimensions of data

Revenue Showdown: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, Arrowhead Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. have been on intriguing revenue trajectories since 2014. Amphastar has consistently outperformed Arrowhead, with its revenue growing by approximately 206% over the past decade, peaking in 2023. In contrast, Arrowhead's revenue, while showing significant growth, remains a fraction of Amphastar's, with a notable spike in 2022, reaching its highest at around 243 million. This disparity highlights Amphastar's robust market strategy and Arrowhead's emerging potential. The data from 2024 is incomplete, suggesting a need for further analysis. As these companies continue to innovate, their financial performances will be crucial indicators of their market positions. Stay tuned for more insights as we delve deeper into the pharmaceutical industry's financial dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025